Andrea Small-Howard

Dr. Andrea Small-Howard has more than 20 years of scientific research experience; as well as executive experience in the biopharmaceutical industry supervising research and development, manufacturing, and quality control divisions in both the US and China. Dr. Small-Howard has taken novel biological products from ideation through commercialization.

Dr. Small-Howard has been named an inventor on more than sixty patent applications and taken the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (“US FDA”) and numerous international regulatory agencies. Currently, Dr. Andrea Small-Howard leverages her broad biopharmaceutical industry knowledge as the Chief Science Officer and member of the Board of Directors at both GB Sciences, Inc. (OTCQB:GBLX), and their wholly-owned Canadian subsidiary, GBS Global Biopharma, Inc. Dr. Small-Howard brings her passion for advancing research on phytochemical compounds to her current roles.

She envisages bringing more phytomedicines to market through an innovative AI-based drug discovery engine and biopharmaceutical drug development program for disease-specific indications. Dr. Small-Howard has worked on cannabinoids for over 20 years, leading a project group dedicated to the study of cannabinoids in the immune system as an NIH-funded post-doctoral fellow. In this work she published one of the earliest studies of cannabinoid impacts on pro-inflammatory immunocytes.

More recently she has contributed to published studies on consumer protection issues surrounding ‘medicinal’ Cannabis chemovars in Nevada, co-authored scholarly reviews on cannabinoids in heart disease and Parkinson’s Disease (PD), co-authored mechanistic studies on cannabinoid and terpene regulation of ion channels, and co-authored an innovative study demonstrating the utility of nanoparticles as delivery vehicles for Cannabis-derived therapeutic compounds.

Dr. Small-Howard is the architect of a strategic vision at GB Sciences/GBS Global Biopharma to make safe, effective, standardized cannabinoid medicines available to patients where its use can be supported with rigorous evidence. To achieve standardization in their cannabinoid-containing, optimized therapeutic mixtures, the Company is using synthetic cannabinoids produced under current Good Manufacturing Practices (cGMP), which are identical in both structure and function to the homologous plant cannabinoids.